Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
candidate save search
Response Pharmaceuticals’ Drug Candidate for the Treatment of Antipsychotic-Induced Weight Gain (AIWG) Achieves Primary Endpoint in Phase 1b Clinical Trial
Published: 2024-04-23 (Crawled : 14:30) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
drug candidate treatment for trial response
Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis
Published: 2024-04-17 (Crawled : 15:00) - biospace.com/
AFMD | $5.22 4.4% 4.21% 22K
|
Health Technology
|
| O: -2.42%
H: 0.0%
C: 0.0%
allonk first candidate lupus cell trial therapy
Valkey Community Announces Release Candidate Amid Growing Support for Open Source Data Store
Published: 2024-04-16 (Crawled : 16:00) - prnewswire.com
SNAP | News S | $11.4 2.33% 0.0% 26M
|
Technology Services
|
| O: -0.87%
H: 0.0%
C: 0.0%
ERIC | News | $5.355 1.81% 1.77% 16M
|
Electronic Technology
|
| O: 2.82%
H: 0.2%
C: -4.5%
candidate for growing store
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
LXEO | News | $12.17 -3.87% -4.03% 82K
|
|
| O: 5.32%
H: 0.0%
C: -2.63%
lx2006 fda candidate granted treatment designation for therapeutics therapy
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
VYGR | News | $7.645 0.99% 0.98% 370K
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: -4.77%
SGMO | News | $0.5212 2.18% 2.13% 2.3M
|
Health Technology
|
| O: 3.13%
H: 0.38%
C: -2.68%
NBIX | News M | $140.11 4.83% 4.6% 1.6M
|
Health Technology
|
| O: -2.15%
H: 2.58%
C: 0.92%
candidate payment for collaboration program therapeutics milestone
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
Published: 2024-04-16 (Crawled : 07:00) - globenewswire.com
NBIX | News M | $140.11 4.83% 4.6% 1.6M
|
Health Technology
|
| O: -2.15%
H: 2.58%
C: 0.92%
nbi-1117 pharma candidate schizophrenia
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
CANF | $1.97 -0.51% 2.03% 3.8K
|
Health Technology
|
| O: 4.76%
H: 0.45%
C: -5.91%
drug candidate liver cancer treat namodenoson advanced
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K
|
Professional, Scientific, and T...
|
| O: -3.83%
H: 0.0%
C: 0.0%
breast cancer preclinical for
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
Published: 2024-04-10 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
IPHA | $2.425 -7.02% 2.7K
|
Health Technology
|
| O: -3.85%
H: 1.2%
C: 0.8%
iph45 pharma drug candidate antibody preclinical
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
CADL | $5.94 7.22% 6.73% 450K
|
|
| O: 3.99%
H: 4.32%
C: -18.56%
candidate tumors preclinical immunotherapy for therapeutics
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
Published: 2024-04-07 (Crawled : 20:20) - globenewswire.com
BNTX | News | $88.53 0.59% 0.59% 360K
|
Health Technology
|
| O: 1.38%
H: 0.2%
C: -1.27%
candidate cancer pancreatic tumor immunotherapy for response show
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-04-05 (Crawled : 19:00) - globenewswire.com
CDTX | News | $0.5141 0.04% 0.04% 1.9M
|
Health Technology
| Email alert
Add to watchlist
association cancer research for meeting therapeutics
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-05 (Crawled : 14:30) - biospace.com/
IMNM | $14.64 -4.19% -4.37% 890K
|
Health Technology
|
| O: -0.44%
H: 3.37%
C: 0.45%
im-3050 association cancer research preclinical for meeting therapy
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
Published: 2024-04-05 (Crawled : 12:00) - globenewswire.com
LIPO | $0.702 -2.5% -2.56% 10K
|
|
| O: -0.6%
H: 6.74%
C: 6.74%
candidate asco pharmaceuticals preclinical for
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
Published: 2024-04-04 (Crawled : 00:00) - biospace.com/
TEVA | $13.01 1.01% 0.0% 8.9M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
candidate biosimilar global for teva agreement
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
CTMX | $1.68 0.6% 0.6% 290K
|
Health Technology
|
| O: -0.47%
H: 2.35%
C: 0.94%
probody candidate t-cell collaboration therapeutics
BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
BETR | $0.4245 0.83% 0.82% 520K
|
n/a
|
| O: -0.96%
H: 0.97%
C: -0.95%
BETRF | $0.0745 -3.71% 550
|
Health Technology
|
| O: -7.53%
H: 7.0%
C: 7.0%
betr-001 drug candidate million
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
Published: 2024-04-01 (Crawled : 12:00) - prnewswire.com
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: -1.03%
H: 0.62%
C: -3.53%
covid-19 candidate vaccine congress world
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
SLDB | $9.08 0.44% 0.44% 300K
|
Health Technology
|
| O: -9.02%
H: 0.0%
C: -7.65%
sgt-003 fda rare candidate disease designation duchenne therapy
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Published: 2024-03-26 (Crawled : 06:00) - globenewswire.com
DVAX | $11.75 -0.76% -0.77% 1.4M
|
Health Technology
|
| O: 0.72%
H: 0.4%
C: -1.75%
candidate vaccine valneva trial
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 870K
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.